非布司他治疗痛风疗效怎么样呢？

Animal experiments show that compared with allopurinol, the effect is 10 to 30 times stronger. The structure of febuxostat is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes involved in purine and pyrimidine metabolism. Allopurinol is a purine analogue, which can affect the activity of other enzymes involved in purine and pyrimidine metabolism in the body, and is prone to some adverse reactions. The specificity of the inhibitory effect of febuxostat can avoid these possible adverse reactions. Febuxostat is completely absorbed after oral administration, with a bioavailability of about 85%, a peak time of about 1 hour, and a half-life of 5 to 8 hours. Food and antacids have no significant effect on the absorption of febuxostat. Today we will learn more about the efficacy of febuxostat in treating gout.

Research results show that long-term use of febuxostat can maintain long-term blood uric acid in most patients at ≤6.0 mg/dl. Mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of febuxostat. Therefore, the uric acid-lowering effect of febuxostat is no different from that of patients with normal renal function, and its safety is good. In short, febuxostat has a better uric acid-lowering effect than allopurinol without serious adverse reactions, and has good clinical application prospects. 

  A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat in gout. A total of 136 male and 17 female gout patients were randomly assigned to receive placebo or this product (40, 80 or 120 mg/d). After 4 weeks, tests found that the serum uric acid concentration of patients in each dose group of this product was significantly lower than before treatment. According to the dose, each group decreased by an average of 37%. %, 44% and 59%, while the patients in the placebo group only decreased by 2%; the vast majority of patients persisted in completing the trial. The incidence of adverse reactions in this product and the placebo group was similar, and most of these adverse reactions were mild and self-limiting, with common ones including diarrhea, pain, back pain, headache and joint pain.

Febuxostat was started at 10 mg/day for 2 weeks, then increased to 20 mg/day for 4 weeks, then to 40 mg/day. Starting with a low dose and gradually increasing the dose can prevent acute gout attacks caused by initial changes in blood uric acid levels. Treat at 40 mg/day for 6 months, and review uric acid levels regularly. Generally, it takes 6 months to clean up excess blood uric acid in the body.